Related Experiment Video
Updated: Nov 6, 2025

Implantation of Total Artificial Heart in Congenital Heart Disease
Published on: July 18, 2014
Flecainide toxicity late after liver transplantation
Ossama Elsaid1, Kristen M Tecson2,3, Hafiza Khan4
1Division of Cardiology, Department of Internal Medicine, Baylor University Medical Center, Dallas, Texas.
Abstract:
Flecainide is an antiarrhythmic agent indicated for patients with supraventricular arrhythmias without ischemic or structural heart disease. Flecainide toxicity is a rare condition in which patients may present with bradycardia, widening of QRS, PR prolongation, ventricular tachycardia, syncope, malaise, dizziness, visual disturbance, nausea, vomiting, and/or lethargy. It carries an associated mortality rate of approximately 10%. Herein, we describe the course of a patient who experienced flecainide toxicity in the setting of renal and liver failure.
More Related Videos
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

